About DBI

Company History & Milestones

2025
Current Focus Areas

  • Focus on DBI-CorBreath – a new solution for chronic disease monitoring; Extension of DBI’s Breath Metabolome contract research
2024
Strategic Pivot and Breakthrough

  • Strategic pivot; IVDR certification of the DBI
    -BreathCollector; successful proof-of-concept study in decentralized chronic disease monitoring at USZ
2023
DBI-BreathCollector

  • Development start of the DBI-BreathCollector; collaboration with AstraZeneca
2022

First IVD-Certified Product Launch

  • Launched DBI-Epibreath — first IVD-certified Therapeutic Drug Monitoring (TDM) software for epilepsy and valproate therapy; collaboration with Bayer
2021

Launch of DBI-Research App and Strategic Collaborations

  • DBI-Research app goes live for research collaborations, clinical studies, and breath database development; collaborations with GSK and Löwenstein
2020

Core Team Formation and Rebranding

  • Established core team and rebranded to Deep Breath Intelligence AG
2019

Initial Partnerships and Platform Launch

  • Provided two SESI-HRMS platforms to partner with UKBB and USZ
2018

Founding and Early Identity

  • Founded in 2018 as Deep Breath Initiative AG